Kiniksa Pharmaceuticals International (KNSA) Common Equity (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Common Equity for 10 consecutive years, with $654.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 32.15% year-over-year to $654.1 million; the trailing twelve-month figure through Jun 2026 stood at $654.1 million (up 32.15% YoY), and the FY2025 full-year result was $567.6 million, up 29.46% from the prior year.
• Common Equity grew to $654.1 million in Q2 2026 per KNSA's latest filing, from $605.7 million in the prior quarter.
• Across five years, Common Equity topped out at $654.1 million in Q2 2026 and bottomed at $153.5 million in Q2 2022.
• Historically, Common Equity has averaged $433.5 million across 5 years, with a median of $436.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity plunged 38.59% in 2022, then soared 168.19% in 2023.
• Over 5 years, Common Equity stood at $396.1 million in 2022, then rose by 10.78% to $438.8 million in 2023, then slipped by 0.09% to $438.4 million in 2024, then climbed by 29.46% to $567.6 million in 2025, then increased by 15.25% to $654.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $654.1 million, $605.7 million, and $567.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.